Retrophin obtains exclusive option to purchase Censa post proof-of-concept study Phase 2 proof-of-concept study in PKU patients expected to commence in mid-2018 SAN DIEGO , Jan. 05, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced a joint development agreement with Censa
SAN DIEGO , Dec. 28, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage , chief executive officer, will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 11, 2018 at 9:30 a.m. PT .
SAN DIEGO , Nov. 30, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage , chief executive officer, will present at the BMO 2017 Prescriptions for Success Healthcare Conference in New York City on Thursday, December 14, 2017 at 3:00 p.m. ET .
Phase 3 FORT Study of fosmetpantotenate continues to enroll PKAN patients Third quarter revenues increased 19 percent to $40 million SAN DIEGO, CALIFORNIA -- (Marketwired) -- 11/07/17 -- Retrophin, Inc. (NASDAQ:RTRX) today reported its third quarter 2017 financial results and provided a corporate
Progressive reduction in proteinuria and stable eGFR observed in open-label treatment period Findings presented at ASN Kidney Week 2017 SAN DIEGO , Nov. 03, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced new positive data from the ongoing open-label extension of the Phase
SAN DIEGO , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage , chief executive officer, will present at the Jefferies 2017 London Healthcare Conference in London, UK on Thursday, November 16, 2017 at 1:20 p.m. GMT ( 8:20 a.m. ET ).
SAN DIEGO , Oct. 24, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report third quarter 2017 financial results on Tuesday, November 7, 2017 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial
SAN DIEGO , Oct. 13, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that it will present new data from the open label extension portion of the Phase 2 DUET study of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disorder, at the
Patient with PKAN showed persistent improvement in function over 30-month period of treatment with fosmetpantotenate SAN DIEGO , Oct. 05, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the presentation of new data from physician-initiated treatment with fosmetpantotenate
SAN DIEGO , Sept. 11, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage , chief executive officer, will present at two upcoming investor conferences in New York City , including: Cantor Fitzgerald Global Healthcare Conference Date: Monday, September 25,
